Portal de Periódicos da CAPES

Dr. Meltzer and Mr. Cola Reply

1995; American Psychiatric Association; Volume: 152; Issue: 1 Linguagem: Alemão

10.1176/ajp.152.1.153

1535-7228

Herbert Y. Meltzer, Philip A. Cola,

Treatment of Major Depression

Back to table of contents Previous article Next article ArticleNo AccessDr. Meltzer and Mr. Cola ReplyHERBERT Y. MELTZER, and PHILIP COLAHERBERT Y. MELTZER, and PHILIP COLAPublished Online:1 Apr 2006https://doi.org/10.1176/ajp.152.1.153AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail "Dr. Meltzer and Mr. Cola Reply." American Journal of Psychiatry, 152(1), pp. 153–154 Access content To read the fulltext, please use one of the options below to sign in or purchase access. Personal login Institutional Login Sign in via OpenAthens Register for access Purchase Save for later Item saved, go to cart PPV Articles - American Journal of Psychiatry $35.00 Add to cart PPV Articles - American Journal of Psychiatry Checkout Please login/register if you wish to pair your device and check access availability. Not a subscriber? Subscribe Now / Learn More PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development. Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.). FiguresReferencesCited byDetailsCited byCritical appraisal of major depression with suicidal ideation31 May 2019 | Annals of General Psychiatry, Vol. 18, No. 1Clozapine augmentation strategies – a systematic meta-review of available evidence. Treatment options for clozapine resistance30 January 2019 | Journal of Psychopharmacology, Vol. 33, No. 4Ultra-Low-Dose Buprenorphine as a Time-Limited Treatment for Severe Suicidal Ideation: A Randomized Controlled TrialYoram Yovell, M.D., Ph.D., Gali Bar, Ph.D., Moti Mashiah, M.D., Yehuda Baruch, M.D., Irina Briskman, M.D., Jack Asherov, M.D., Amit Lotan, M.D., Amihai Rigbi, Ph.D., Jaak Panksepp, Ph.D.18 December 2015 | American Journal of Psychiatry, Vol. 173, No. 5Der Nervenarzt, Vol. 87, No. 5Suizidalität26 November 2016Revisiting loxapine: a systematic review1 April 2015 | Annals of General Psychiatry, Vol. 14, No. 1Current Treatment Options in Psychiatry, Vol. 1, No. 2Nordic Journal of Psychiatry, Vol. 68, No. 6Analysis of treatment-resistant schizophrenia and 384 markers from candidate genesPharmacogenetics and Genomics, Vol. 22, No. 11The International Journal of Neuropsychopharmacology, Vol. 15, No. 09Forms of antipsychotic therapy: improved individual outcomes under personalised treatment of schizophrenia focused on depression12 August 2011 | EPMA Journal, Vol. 2, No. 4Suicidal behavior in the older patient with schizophreniaAging Health, Vol. 7, No. 3, Vol. 22Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics1 September 2009 | Molecular Psychiatry, Vol. 16, No. 1Neuropsychopharmacology, Vol. 36, No. 3Neuropsychopharmacology, Vol. 36, No. 3CNS Drugs, Vol. 25, No. 2Neuropsychiatry, Vol. 1, No. 6Economics of the Treatment of Schizophrenia8 March 2011, Vol. 120Suicidal Behavior in SchizophreniaJournal of Nervous & Mental Disease, Vol. 197, No. 3Neuropsychopharmacology, Vol. 34, No. 1Expert Opinion on Pharmacotherapy, Vol. 9, No. 18Expert Review of Neurotherapeutics, Vol. 8, No. 1International Clinical Psychopharmacology, Vol. 22, No. 5Acta Psychiatrica Scandinavica, Vol. 115, No. 2Annals of General Psychiatry, Vol. 6, No. 1CNS Drugs, Vol. 21, No. 4Antipsychotic Medications, Schizophrenia and the Issue of Quality of LifecDNA array reveals increased expression of glucose-dependent insulinotropic polypeptide following chronic clozapine treatment: role in atypical antipsychotic drug-induced adverse metabolic effects13 December 2005 | The Pharmacogenomics Journal, Vol. 6, No. 2Diabetologia, Vol. 49, No. 12The European Journal of Health Economics, Vol. 7, No. 3Journal of Mental Health, Vol. 15, No. 4Cognitive Neuropsychiatry, Vol. 11, No. 3Pharmacogenetic Testing in the Clinical Management of SchizophreniaJournal of Clinical Psychopharmacology, Vol. 25, No. 5Suicide PreventionCrisis, Vol. 26, No. 3American Journal of Medical Genetics Part C: Seminars in Medical Genetics, Vol. 133C, No. 1European Journal of Clinical Pharmacology, Vol. 60, No. 11European Archives of Psychiatry and Clinical Neuroscience, Vol. 255, No. 2Nature Genetics, Vol. 37, No. 7Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs3 August 2004 | Molecular Psychiatry, Vol. 10, No. 1Annals of Clinical Psychiatry, Vol. 17, No. 3Archives of Suicide Research, Vol. 9, No. 3Archives of Suicide Research, Vol. 9, No. 3The World Journal of Biological Psychiatry, Vol. 6, No. 4The World Journal of Biological Psychiatry, Vol. 6, No. 3International Clinical Psychopharmacology, Vol. 20, No. 4Psychiatry and Clinical Neurosciences, Vol. 59, No. 2Psychiatry and Clinical Neurosciences, Vol. 59, No. 3Verhaltenstherapie, Vol. 15, No. 1Verhaltenstherapie, Vol. 15, No. 1CNS Drugs, Vol. 19, No. 10Treatment-refractory schizophrenia1 April 2022 | Dialogues in Clinical Neuroscience, Vol. 6, No. 1Investigation of M1/M4 Muscarinic Receptors in the Anterior Cingulate Cortex in Schizophrenia, Bipolar Disorder, and Major Depression Disorder17 December 2003 | Neuropsychopharmacology, Vol. 29, No. 3Issues in Mental Health Nursing, Vol. 25, No. 1Nordic Journal of Psychiatry, Vol. 58, No. 2Antisuicide Properties of Psychotropic Drugs: A Critical ReviewHarvard Review of Psychiatry, Vol. 12, No. 1The World Journal of Biological Psychiatry, Vol. 5, No. 4Bulletin of the Menninger Clinic, Vol. 68, No. 4CNS Drugs, Vol. 18, No. 13The Treatment of SchizotaxiaNature Reviews Neuroscience, Vol. 4, No. 10Neuropsychopharmacology, Vol. 28, No. 1Neuropsychopharmacology, Vol. 28, No. 3The World Journal of Biological Psychiatry, Vol. 4, No. 4Diabetes Technology & Therapeutics, Vol. 5, No. 4Bipolar Disorders, Vol. 5, No. s2Drugs, Vol. 63, No. 21New Pyridobenzodiazepine Derivatives: Modifications of the Basic Side Chain Differentially Modulate Binding to Dopamine (D 4.2 , D 2L ) and Serotonin (5-HT 2A ) Receptors8 October 2002 | Journal of Medicinal Chemistry, Vol. 45, No. 23Clozapine-Induced Stuttering and SeizuresHARPREET S. DUGGAL, M.B.B.S., D.P.M., K. JAGADHEESAN, M.B.B.S., M.D., and S. HAQUE NIZAMIE, M.D., D.P.M., 1 February 2002 | American Journal of Psychiatry, Vol. 159, No. 2Transcranial Magnetic Stimulation for PanicPETER ZWANZGER, M.D., CHRISTO MINOV, M.D., ROBIN ELLA, M.D., CORNELIUS SCHÜLE, M.D., THOMAS BAGHAI, M.D., HANS-JÜRGEN MÖLLER, M.D., RAINER RUPPRECHT, M.D., and FRANK PADBERG, M.D., 1 February 2002 | American Journal of Psychiatry, Vol. 159, No. 2Current Psychiatry Reports, Vol. 4, No. 4Current Opinion in Psychiatry, Vol. 15International Clinical Psychopharmacology, Vol. 17, No. 5Clinical Drug Investigation, Vol. 22, No. 5Symptom Reduction and Suicide Risk Among Patients Treated With Placebo in Antipsychotic Clinical Trials: An Analysis of the Food and Drug Administration DatabaseArif Khan, M.D., Shirin R. Khan, Robyn M. Leventhal, B.A., and Walter A. Brown, M.D.1 September 2001 | American Journal of Psychiatry, Vol. 158, No. 9Diagnosis and Treatment of Mood Disorders That Co-occur With SchizophreniaMichael A. Escamilla, M.D.1 July 2001 | Psychiatric Services, Vol. 52, No. 7Impact of Clozapine on Completed SuicideMichael J. Sernyak, M.D., Rani Desai, Ph.D., Marilyn Stolar, M.A., and Robert Rosenheck, M.D.1 June 2001 | American Journal of Psychiatry, Vol. 158, No. 6A Review of Suicide within the State Hospital, Carstairs 1972–199625 June 2016 | Medicine, Science and the Law, Vol. 41, No. 2Atypical Antipsychotics: New Directions and New Challenges in the Treatment of SchizophreniaAnnual Review of Medicine, Vol. 52, No. 1Drug Development Research, Vol. 54, No. 2International Clinical Psychopharmacology, Vol. 16, No. Supplement 1Expert Opinion on Therapeutic Targets, Vol. 5, No. 6Journal of Medical Economics, Vol. 4, No. 1-4Depression in Schizophrenia: Perspective in the Era of "Atypical" Antipsychotic AgentsSamuel G. Siris, M.D.1 September 2000 | American Journal of Psychiatry, Vol. 157, No. 9An Assessment of Clinical Practice of Clozapine Therapy for VeteransMartha Sajatovic, M.D., C. Raymond Bingham, Ph.D., David Garver, M.D., Luis F. Ramirez, M.D., Gary Ripper, M.A., Frederic Blow, Ph.D., and Laurent S. Lehmann, M.D.1 May 2000 | Psychiatric Services, Vol. 51, No. 5Depression and Anxiety, Vol. 11, No. 2Journal of Clinical Psychology, Vol. 56, No. 9The Privilege and Responsibility of Suicide Prevention*Presidential Address, presented at the 20th Congress of the International Association for Suicide Prevention, Athens, Greece, 6-10 November 1999.Crisis, Vol. 21, No. 1Nordic Journal of Psychiatry, Vol. 54, No. 2International Journal of Psychiatry in Clinical Practice, Vol. 4, No. 1, Vol. 20000744Expert Opinion on Pharmacotherapy, Vol. 1, No. 2CNS Drugs, Vol. 13, No. 2CNS Drugs, Vol. 13, No. 6CNS Drugs, Vol. 14, No. 5The World Journal of Biological Psychiatry, Vol. 1, No. 4Clozapine associated with decreased suicidality in bipolar disorder: a case report24 December 2001 | Bipolar Disorders, Vol. 1, No. 2Cognition, schizophrenia, and the atypical antipsychotic drugs23 November 1999 | Proceedings of the National Academy of Sciences, Vol. 96, No. 24Treatment of Schizoaffective Disorder and Schizophrenia With Mood SymptomsDouglas F. Levinson, M.D., C. Umapathy, M.D., and Mohamado Musthaq, M.D.1 August 1999 | American Journal of Psychiatry, Vol. 156, No. 8Clinical Outcome in a Randomized 1-Year Trial of Clozapine Versus Treatment as Usual for Patients With Treatment-Resistant Illness and a History of ManiaTrisha Suppes, M.D., Ph.D., Andrew Webb, B.A., Betty Paul, L.V.N., Thomas Carmody, Ph.D., Helena Kraemer, Ph.D., and A. John Rush, M.D.1 August 1999 | American Journal of Psychiatry, Vol. 156, No. 8Improvement of Schizophrenic Patients With Primary Negative Symptoms Treated With AmisulprideJean-Marie Danion, M.D., Werner Rein, M.D., Odile Fleurot, M.D., and the Amisulpride Study Group1 April 1999 | American Journal of Psychiatry, Vol. 156, No. 4Impact of Clozapine on Negative Symptoms and on the Deficit Syndrome in Refractory SchizophreniaRobert Rosenheck, M.D., Lawrence Dunn, M.D., Michael Peszke, M.D., Joyce Cramer, Weichun Xu, Ph.D., Jonathan Thomas, M.S., Dennis Charney, M.D., and the Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia1 January 1999 | American Journal of Psychiatry, Vol. 156, No. 1Current Psychiatry Reports, Vol. 1, No. 1Critical Care Medicine, Vol. 27, No. 3International Journal of Psychiatry in Clinical Practice, Vol. 3, No. 4Conventional Psychotropic-Induced Tremor Extinguished by OlanzapineArthur J.L. Strauss, M.D., , Rahn K. Bailey, M.D., , Penelope W. Dralle, Ph.D., , Anthony J. Eschmann, B.C.S.W., and , and Richard B. Wagner, M.S.W., M.U.R.P., , 1 August 1998 | American Journal of Psychiatry, Vol. 155, No. 8Book Review ChallengedJudd Marmor, M.D., 23 January 2015 | American Journal of Psychiatry, Vol. 155, No. 8Positive and Negative Symptom Response to Clozapine in Schizophrenic Patients With and Without the Deficit SyndromeRobert W. Buchanan, M.D., Alan Breier, M.D., Brian Kirkpatrick, M.D., Patricia Ball, R.N., and William T. CarpenterJr., M.D.1 June 1998 | American Journal of Psychiatry, Vol. 155, No. 6Neuroendocrine Evidence That Clozapine's Serotonergic Antagonism Is Relevant to Its Efficacy in Treating Hallucinations and Other Positive Schizophrenic SymptomsHugh Jones, M.B., B.S., Vivienne A. Curtis, M.R.C.Psych., Padraig Wright, M.D., M.R.C.Psych., and James V. Lucey, M.D., M.R.C.P.I., M.R.C.Psych.1 June 1998 | American Journal of Psychiatry, Vol. 155, No. 6Medical Complications and Selectivity of Therapeutic Response to Atypical Antipsychotic DrugsDiana O. Perkins, M.D., M.P.H., and Jeffrey A. Lieberman, M.D.1 February 1998 | American Journal of Psychiatry, Vol. 155, No. 2Trends in Pharmacological Sciences, Vol. 19, No. 4New England Journal of Medicine, Vol. 338, No. 4Nordic Journal of Psychiatry, Vol. 51, No. sup40Nordic Journal of Psychiatry, Vol. 52, No. 1Archives of Suicide Research, Vol. 4, No. 4International Journal of Psychiatry in Clinical Practice, Vol. 2, No. 1International Journal of Psychiatry in Clinical Practice, Vol. 2, No. 3Time to clozapine response in a standardized trial1 April 2006 | American Journal of Psychiatry, Vol. 154, No. 9Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial1 April 2006 | American Journal of Psychiatry, Vol. 154, No. 4Human Psychopharmacology: Clinical and Experimental, Vol. 12, No. 4New England Journal of Medicine, Vol. 337, No. 12Archives of Suicide Research, Vol. 3, No. 2Current Medical Research and Opinion, Vol. 14, No. 1Expert Opinion on Investigational Drugs, Vol. 6, No. 11Time required for initial improvement during clozapine treatment of refractory schizophrenia1 April 2006 | American Journal of Psychiatry, Vol. 153, No. 7New England Journal of Medicine, Vol. 334, No. 1Current Opinion in Psychiatry, Vol. 9, No. 1Clozapine: is another view valid?1 April 2006 | American Journal of Psychiatry, Vol. 152, No. 6 Volume 152Issue 1 January 1995Pages 153-154 Metrics PDF download History Published online 1 April 2006 Published in print 1 January 1995